Concepedia

Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer

Roberto Iacovelli, Chiara Ciccarese, Claudia Mosillo, Davide Bimbatti, Emanuela Fantinel, Lisa Stefani, Michele Simbolo, Mario Romano, Renzo Mazzarotto, Matteo Brunelli,

Targeted Oncology · 2018 · 27 citations · 21 references

DOI

Concepts

References

21

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text

, , +15

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Karim Fizazi, NamPhuong Tran, Luis Fein et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

, , +15

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James, Matthew R. Sydes, Noel W. Clarke et al. · The Lancet · 2015 · 2K citations · Full text

, , +17

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

Nicholas D. James, Johann S. de Bono, Melissa Spears et al. · New England Journal of Medicine · 2017 · 1.8K citations · Full text

, , +14

International Variation in Prostate Cancer Incidence and Mortality Rates

Ahmedin Jemal, Joannie Lortet‐Tieulent, Elizabeth Ward et al. · European Urology · 2012 · 1.5K citations

, , +16